MicroRNAs (miRNAs) are tiny RNA molecules that regulate gene expression by controlling messenger RNAs (mRNAs) and are ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Immunotherapy employs patients' own immune systems to fight cancer, and it has shown itself to be an effective treatment in ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...

Reprogrammable RNA nanoparticles activate only in cancer cells to deliver targeted gene-silencing therapy while avoiding ...

“Newer RNA interference therapeutics, patisiran and vutrisiran, show significant promise as an effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM),” Farhan Naeem, MD, from ...

A team of researchers from the Spanish National Research Council has made a significant advance in plant biotechnology by ...

Sarepta Therapeutics (NASDAQ:SRPT) has announced the sale of about 9.3M shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...